State Pharmacopoeia of Ukraine: present and future Maryna Dmitriieva Scientific Secretary of Ukrainian Scientific Pharmacopoeial Centre for Quality of.

Slides:



Advertisements
Similar presentations
Current Status of Science, Technology and Innovation Policy Review in Tanzania Mayunga H.H. Nkunya Executive Secretary, Tanzania Commission for Universities.
Advertisements

EPAA Conference 5 November 2007 Georgette LALIS Enterprise and Industry DG European Commission The international dimension of regulatory acceptance.
World Health Organization
Current Issues & Challenges in the Development of Pharmacopoeial Monographs: European Pharmacopoeia Dr. Susanne Keitel European Directorate for the Quality.
ICH Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC) Overview and Update Robert H. King, Sr. Office of Pharmaceutical.
A Brief Presentation of PRESS OO For the CIDOC CRM SIG and FRBR/CRM Harmonisation WG 21 October 2013.
World Health Organization
SOURCES OF PHARMACEUTICAL INFORMATION. 1-Pharmacopeias Pharmacopoeia is a book containing an official list of the drugs used in medicine together with.
1 Dr S. Kopp WHO's normative functions in the field of pharmaceuticals WHO Expert Committee on Specifications for Pharmaceutical Preparations Secretary:
Role of Compendial Standards and Verification Programs to Safeguard the Global Supply Chain FDLI Conference on Safeguarding the Functional Food and Dietary.
Lecture – DR. SHAHNAZ USMAN Associate Professor Dept. of Pharmaceutics RAKMHSU PHARMACOPOEIAS AND OTHER OFFICIAL COMPENDIA 1.
Workshop on Medicines Regulation in the Caribbean Barbados, September 8-9, 2009 Essential Regulatory Functions: Quality Assurance The CRDTL Experience.
Structure of Dossier of Medicinal Product- Q part
Presented by: Karen Ginsbury For IFF, Denmark March 2012.
FUNCTIONAL FOODS Samantha Richards NUTR 243. Overview How to define “functional foods” Common misconceptions Regulation of functional foods Categories.
Development of the National System of Medicine Reference Substances in Ukraine Leontiev Dmytro Deputy director (science) Group Manager “Validation and.
Mosby items and derived items © 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 1 Information, Sources, and Regulatory Agencies.
Draft Code of Practice – General Consultation / Implementation Sue Woodgate.
INTERNATIONAL MEETING OF WORLD PHARMACOPOEIAS 29 February to 2 March 2012 WHO, Geneva 1.
RPS Publishing Dr. Laszlo Horvath. Overview Brief History Brief History RPS Publishing – Imprints RPS Publishing – Imprints Pharmaceutical Press Products.
Quality of Substances for Pharmaceutical Use: The EDQM Certification of Suitability to the European Pharmacopoeia Monographs (CEP) Dr. Susanne Keitel DIA.
Radiopharmaceutical Production
The International Pharmacopoeia Overview Caroline Mendy Technical Officer - Quality Assurance and Safety: Medicines Quality of Active Pharmaceutical Ingredients,
1 Impurities: Positions of the regulatory authorities (like FDA and EMA) worldwide Dr. Christian Zeine, Warsaw, Nov 18, 2014 Science for a safer world.
DMF Procedures and Communication between API, FP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
Monograph Development Process for the European Pharmacopoeia: How to participate in the work programme of the European Pharmacopoeia Dr Claude Coune Head.
Principles of quality control of registered medicines, non- registered medicines and counterfeits of medical products Jean-Marc Spieser, Head of Department.
September 13, 2007SGH&M2B International&Training Workshop What does the European Technology Platform “Innovative Medicines initiative” offer? Vitalijs.
Regulating Herbal Medicines in Europe Heribert PITTNER Federal Ministry of Health and Women, Vienna, Austria 8th European Health Forum Gastein 7 October.
Nanomaterials classification and labelling – status of work undertaken in GHS (Globally Harmonized System of Classification and Labelling of Chemicals)
The International Pharmacopoeia - The International Pharmacopoeia : One-day Briefing, Geneva | 28 April Overview Caroline Mendy - Technical Officer.
ELDD Reflection – past, present and future 29th Meeting of the Scientific Committee, 18 Nov 2008.
Current issues and challenges in the development of IP monographs Dr. G.N. Singh Secretary-cum-Scientific Director Indian Pharmacopoeia Commission Ghaziabad.
Dietary Supplement Research Centers: Botanicals RFA OD Applicant Information Meeting February 6, 2004 Bethesda MD Christine A. Swanson, Ph.D. Office.
Title of the Project: Modern European Technologies Transfer into Agriculture of Ukraine Title of the Project: Modern European Technologies Transfer into.
© AL IPA/EDQM/IDMA Symposium 2007, All rights reserved The Ph. Eur. policy on impurities Dr Andrea Lodi Deputy Head, Laboratory Department, EDQM, Council.
DISCOVERY HEALTH COMMENTS ON THE MEDICINES AND RELATED SUBSTANCES BILL August 2008.
FORMATION AND FUNCTIONING OF INDIAN PHARMACOPOEIA COMMISSION (IPC) By Dr G N Singh Member-Secretary.
1 FDA Guidance for Industry: ANDAs: Impurities in Drug Substances Published by US FDA’s Center for Drug Evaluation and Research June 2009.
The Male’ Declaration Proposal for Phase 4 Implementation.
Common Implementation Strategy for the Water Framework Directive Planning of a Workshop CLIMATE CHANGE IMPACTS ON THE WATER CYCLE, RESOURCES AND QUALITY.
PRESENTATION OF BREAKAWAY SESSION THEME – I HARMONIZATION AND INTERNATIONAL COOPERATION IN TM SHIV BASANT Joint Secretary Department of AYUSH, India.
1 Copyright © 2015, 2011, 2007 Pearson Education, Inc. Chapter 1-1 Basic Concepts Chapter 1.
International conference Quality of Active Pharmaceutical Ingredients Hyderabad, September 2009 API Inspections: the EDQM experience – 7 September.
1 IFAD consideration of a Code of Conduct for Executive Board Representatives Historical Background Presentation to an Informal Seminar of the Executive.
IPEC Overview The Impact of Globalisation and IPEC’s Role Janeen Skutnik Past Chair – IPEC Americas.
Regulation 13-H Transitional Provisions Presentation in conjunction with ECE/TRANS/WP29/GRRF/2014/16 Prepared by the ad hoc group on Transitional Provisions.
Implementation of PANDRH Guidelines NAFTA Region VI PANDRH Conference Brasilia, July 2-8, 2011 Justina Molzon -- US Food and Drug Administration Mike Ward.
USP: Water for Pharmaceutical Purposes NCSLI – Metrological Traceability in Pure Water Testing August 22, 2011 Antonio Hernandez-Cardoso Senior Scientific.
DMF Procedures and Communication between API, FFP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
CHAPTER 8 Global Use of Complementary and Alternative Medicine (CAM) and Treatments.
Unit 10 pharmacopoeia Text A The United States pharmacopeia.
Assessing Herbal Medicine Research Productivity Chia-Yu Wu 1 *, Yee-Shuan Lee 2 and Yuh-Shan Ho 1# 1 School of Public Health, Taipei Medical University.
Quality Control of Herbal Drug
Summary of component 9: Statistical Business Register
Swissmedic Pharmacopoeia Unit (NPA)
RPS Publishing Presentation to INFORMATIO MEDICATA 2006 by Maryam Kazemi 17 October 2006.
Ruban Anna PhD student Department of Environmental Sciences and Policy
Overview of vaccines prequalification
Intercalibration excersice progress report Presented by Palle Haastrup Joint Research Centre Institute for Environment and Sustainability Inland.
5. STATUS OF THE PRIORITY AREAS IMPLEMENTATION OF THE PLAN FOR THE WIGOS PRE-OPERATIONAL PHASE (PWPP) 5.2 WIGOS Regulatory Material complemented with necessary.
Quality control Lecture 1.
Chapter 1 Basic Concepts.
Success Story of Organic Chemistry -Dr. A.G. Nikalje
Drug regulation and quality assurance:
Quality control Lecture 1.
Chapter Five: Ratios and Proportions
OIE’s standard setting process
The European Pharmacopoeia and Pharmeuropa
Abnormal toxicity test (ATT) -
Presentation transcript:

State Pharmacopoeia of Ukraine: present and future Maryna Dmitriieva Scientific Secretary of Ukrainian Scientific Pharmacopoeial Centre for Quality of Medicines Chinese Pharmacopoeia Scientific Symposium of September, 2015

1 Status of the State Pharmacopoeia of Ukraine

SPU 1 Outcome First pharmacopoeia among the former USSR countries Basis for all other regulation documents for medicines RS system was created Pharmacopoeial Ukrainian language established Handbook and tutorial for students and specialists an observer of the Ph. Eur. Commission 1998 Ukraine is a voting member of the Ph. Eur. Commission 2013 Historical Overview

3 The ratio of SPU 2.0 and Ph. Eur. items GCs and texts Vaccines Immune sera Radiopharmaceuticals Suture material Herbal Drugs Homeopathic API Finished products Compounding Dietary supplements SPU 2.0 Ph.Eur. 8.2 SPU 2.0 features Actualization ~800 GC and Monographs of SPU 1 National parts of many chapters are excluded National parts that remain are for advisory and informational purposes Development FP monographs further development National parts and national monographs for Herbal Drugs and preparations Texts on new areas of medicines (DS,CP)

4 Mechanism of SPU

5 Continuous transition to the direct using of the Ph. Eur. texts without translation Inclusion of the texts which are important for Ukraine but not presented in Ph. Eur. Dietary Supplements Compounded Preparations Metrological support of QC Medicinal cosmetics API Excipients Reagents The concept of SPU further development

6 The concept of SPU further development

7 The concept of SPU further development

8 The concept of SPU further development

9 The concept of SPU further development

10 The concept of SPU further development

11 The concept of SPU further development

12 Dietary Supplements Herbal ingredients Monographs and GCs for Herbal drugs and preparations Compounded Preparations Herbal infusions Herbal teas Honey preparations The concept of SPU further development

13